KDMN Kadmon Holdings Inc.

3.45
-0.08  -2%
Previous Close 3.53
Open 3.49
Price To book -2.30
Market Cap 178870497
Shares 51,846,521
Volume 229,344
Short Ratio 3.11
Av. Daily Volume 475,705

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 3Q 2017.
Tesevatinib
Autosomal dominant Polycystic Kidney Disease (ADPKD)
Phase 2 interim data presented July 11, 2017. ORR 71%.
KD025
Chronic graft-versus-host disease (cGVHD)
Phase 2 data due 4Q 2017.
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 first patient dosed September 2016, approximately 50% enrolled as of August 2017.
KD025
Moderate to severe chronic plaque psoriasis
Phase 2 initiated August 2016. Enrollment ongoing as of May 15, 2017.
Tesevatinib
Recurrent glioblastoma - cancer
Phase 2 data on the first 13 patients to be presented at the IASLC 17th World Conference on Lung Cancer December 6 2016.
Tesevatinib
EGFR-mutant non-small cell lung cancer (NSCLC) that has metastasized to the brain

Latest News

  1. Featured Company News - Kadmon Holdings' KD025 Receives Orphan Drug Designation for the Treatment of cGVHD by FDA
  2. FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD
  3. Kadmon Announces Closing of $80.4 Million Public Offerings and Full Exercise of Over-Allotment Option
  4. Kadmon Announces Pricing of Public Offerings of Common Stock and Warrants
  5. Kadmon Announces Proposed Public Offering of Common Stock and Warrants
  6. ETFs with exposure to Kadmon Holdings, Inc. : September 22, 2017
  7. Kadmon to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  8. ETFs with exposure to Kadmon Holdings, Inc. : August 31, 2017
  9. Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
  10. Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017
  11. FDA Grants Orphan Drug Designation to Kadmon’s Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
  12. Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results
  13. Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
  14. Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
  15. Small Caps Outperform in June: 4 Best ETFs & Stocks
  16. Kadmon Holdings (KDMN) Shares March Higher, Can It Continue?
  17. Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day
  18. ETFs with exposure to Kadmon Holdings, Inc. : June 22, 2017
  19. Kadmon to Present at the Jefferies 2017 Global Healthcare Conference

SEC Filings

  1. 8-K - Current report 171127934
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171124977
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171115004
  4. 8-K - Current report 171105741
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171105063
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171105055
  7. 424B5 - Prospectus [Rule 424(b)(5)] 171100553
  8. 424B5 - Prospectus [Rule 424(b)(5)] 171100550
  9. 8-K - Current report 171100153
  10. 424B5 - Prospectus [Rule 424(b)(5)] 171033925